SMMT
Summit Therapeutics Inc.
$18.08
+5.42%
2026-05-08
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Key Fundamentals
Forward P/E
-15.78
EPS (TTM)
$-1.59
ROE
-271.0%
Profit Margin
0.0%
Debt/Equity
3.67
Price/Book
20.59
Beta
-1.25
Market Cap
$13.58B
Avg Volume (10D)
5.6M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$29.23
60D Low
$14.58
Avg Volume
3.2M
Latest Close
$18.08
Get breakout alerts for SMMT
Sign up for Breakout Scanner to receive daily notifications when SMMT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Summit Therapeutics Inc. (SMMT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SMMT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SMMT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.